Skip to main content
. 2018 Oct 11;8:15175. doi: 10.1038/s41598-018-33290-5

Figure 6.

Figure 6

SHLP2 protects against Amyloid-β-induced cell death. (A) Addition of amyloid-β1–42 active peptide diminished the number of viable cells in normal (NL) cybrid cells compared to their untreated (UN) counterparts (bar 1 vs. bar 2). No significant difference in cell viability was observed between untreated and amyloid-β42–1 SC-treated NL cybrids (bar 1 vs. bar 3). Treatment with SHLP2 significantly increased the cell viability in amyloid-β1–42-treated NL (bar 5) and amyloid-β42–1 SC-treated NL cybrids (bar 6) compared to the ones treated with amyloid-β1–42 alone (bar 2). (B) Amyloid-β1–42-treated AMD cybrids showed reduced number of viable cells compared to the untreated group (bar 1 vs. bar 2) and the amyloid-β42–1 SC-treated group (bar 2 vs. bar 3). SHLP2 pretreatment resulted in a drastic increase in cell viability in amyloid-β1–42-treated (bar 5) and amyloid-β42–1 SC-treated (bar 6) AMD cybrids compared to the AMD cybrids treated with amyloid-β1–42 alone (bar 2). Data are presented as Mean ± SEM and normalized to untreated-normal cybrids which were assigned value of 1. Experiments were performed at the 72 hr time-point.